Did you know?

34%

of FDA-sampled compounded products failed one or more standard quality tests performed, including potency testing.2

Prescribers and patients expect their medication to meet efficacy and safety standards

  • Unlike EPRONTIA™, compounded medications are not FDA approved, meaning the FDA does not verify the safety or effectiveness of the compounded product.3

  • Topiramate is on the list the Institute for Safe Medication Practices maintains of oral dosage forms that should not be crushed.4

  • Variation in dose of topiramate due to incomplete administration of crushed tablets could lead to adverse clinical outcomes.5

Important Safety Information (cont)

Oligohydrosis (decreased sweating) and Hyperthermia: Oligohydrosis, infrequently resulting in hospitalization, has been reported in association with EPRONTIA use. The majority of these reports have been in pediatric patients. Patients, especially pediatric patients, should be monitored for evidence of decreased sweating and increase in body temperature, especially in hot weather. Caution should be used when EPRONTIA is prescribed with other drugs that predispose patients to heat-related disorders. These drugs include, but are not limited to, other carbonic anhydrase inhibitors and other drugs with anticholinergic activity.

Please see additional Important Safety Information throughout, and the accompanying full Prescribing Information.